Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy.

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡ / Conte, P; Frassoldati, A; Bisagni, G; Brandes, A A; Donadio, M; Garrone, O; Piacentini, F; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Molino, A; Musolino, A; Ferro, A; Maltoni, R; Danese, S; Zamagni, Claudio; Rimanti, A; Cagossi, K; Russo, A; Pronzato, P; Giovanardi, F; Moretti, G; Lombardo, L; Schirone, A; Beano, A; Amaducci, L; Bajardi, E A; Vicini, R; Balduzzi, S; D'Amico, R; Guarneri, V. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 29:12(2018), pp. 2328-2333-2333. [10.1093/annonc/mdy414]

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡

Garrone, O;Molino, A;ZAMAGNI, CLAUDIO;Giovanardi, F;
2018

Abstract

Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy.
2018
her 2 , breast cancer, trastuzumab
01 Pubblicazione su rivista::01a Articolo in rivista
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡ / Conte, P; Frassoldati, A; Bisagni, G; Brandes, A A; Donadio, M; Garrone, O; Piacentini, F; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Molino, A; Musolino, A; Ferro, A; Maltoni, R; Danese, S; Zamagni, Claudio; Rimanti, A; Cagossi, K; Russo, A; Pronzato, P; Giovanardi, F; Moretti, G; Lombardo, L; Schirone, A; Beano, A; Amaducci, L; Bajardi, E A; Vicini, R; Balduzzi, S; D'Amico, R; Guarneri, V. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 29:12(2018), pp. 2328-2333-2333. [10.1093/annonc/mdy414]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1275140
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 45
  • Scopus 119
  • ???jsp.display-item.citation.isi??? 107
social impact